Passage Bio Inc. (PASG)
Passage Bio Inc. (PASG) Stock Price, Analysis & Data
Keine Daten verfügbar
| Geld | 3.19 |
| Marktkapitalisierung | 14.54 Mio |
| Umsatz (TTM) | n/a |
| Nettogewinn (TTM) | -36.11 Mio |
| Beta | 1.43 |
| EPS (ttm) | -11.32 |
| KGV (TTM) | n/a |
| Forward-KGV | -0.44 |
| KBV (TTM) | 0.77 |
| KUV (TTM) | n/a |
| Earnings Date | Mar 3, 2026 |
| Brief | 5.76 |
| Volumen | 2,206 |
| Ø Vol. (20D) | 69,927 |
| Eröffnung | 4.52 |
| Vortagesschluss | 4.58 |
| Tagesspanne | 4.42 - 4.67 |
| 52-Wk Range | 3.29 - 20.00 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über PASG
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystr...
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Passage Bio 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -45.52 Mio, ein Rückgang von -29.71 %.
FinanzberichteGewinnüberraschung
Analysten erwarten einen Umsatz von ... Upgrade
vor 3 Monaten · Insider Monkey
Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside?Passage Bio Inc (NASDAQ:PASG) is one of the best gene therapy stocks to buy in 2026. While the stock is down around 50% year-to-date, analysts see it surging 125% over the next 12 months. On April 20,...